EGFR and type 2 diabetes mellitus: (Yıldırım et al., 2023).” EGFR inhibitors (e.g., erlotinib) block hepatocyte regeneration signaling pathways (e.g., RAS-RAF-MEK-ERK), further impairing repair capacity in the context of T2DM (Bak et al., 2025).